Announcements Trials

Browse Landscape

Phase

Phase 3 5 Phase 2 5 Phase 1/2 3 Phase 1 2 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1

Interventions

Cisplatin 22 Magnetic Resonance Spectroscopy 18 Gemcitabine 15 Carboplatin 14 pembrolizumab 13 Specimen Handling 13 Paclitaxel 13 Radiotherapy 10 Nivolumab 10 Bevacizumab 10 atezolizumab 8 Radiation 8 Platinum 8 Pemetrexed 8 Doxorubicin 8 Docetaxel 8 1,2-diaminocyclohexaneplatinum II citrate 8 Drug Therapy 7 Dexamethasone 7 Temozolomide 6 Rituximab 6 Radiotherapy, Intensity-Modulated 6 Prednisone 6 Surgical Procedures, Operative 5 Ipilimumab 5 Immunoglobulin G 5 Disulfides 5 Cytarabine 5 Cyclophosphamide 5 Biopsy 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Alpelisib × 90 days × Clear all

NCT05948943 2026-06-02

EPIK-L1

Novartis

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon ⚡